SEARCH:   Advanced

Blood, 1 November 2008, Vol. 112, No. 9, pp. 3574-3581. Prepublished online as a Blood First Edition Paper on July 7, 2008; DOI 10.1182/blood-2008-02-140095. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-02-140095v1 112/9/3574    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ciceri, F. Articles by Rocha, V. Search for Related Content PubMed PubMed Citation Articles by Ciceri, F. Articles by Rocha, V. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation Fabio Ciceri1, Myriam Labopin2, Franco Aversa3, Jakob M. Rowe4, Donald Bunjes5, Philippe Lewalle6, Arnon Nagler7, Paolo Di Bartolomeo8, João F. Lacerda9, Maria Teresa Lupo Stanghellini1, Emmanuelle Polge2, Francesco Frassoni10, Massimo F. Martelli3, Vanderson Rocha2,11, on behalf of the Acute Leukemia Working Party (ALWP) of the European Blood and Marrow Transplant (EBMT) Group 1 Hematology and BMT Unit, San Raffaele Scientific Institute, Milano, Italy; 2 ALWP, EBMT-Paris Office, Hôpital Saint Antoine Assistance Publique-Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie Paris 6, Paris, France; 3 Hematology, University of Perugia, Perugia, Italy; 4 Rambam Medical Centre Technion, Israel Institute of Technology, Haifa, Israel; 5 University of Ulm, Ulm, Germany; 6 Institut Bordet, Universite libre de Bruxelles, Bruxelles, Belgium; 7 Chaim Sheba Medical Center, Tel Hashomer, Israel; 8 Ospedale Civile, Pescara, Italy; 9 Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal; 10 Hematology, H San Martino Genova, Genova, Italy; and 11 Hôpital Saint-Louis, Paris, France Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an alternative treatment to patients with high-risk acute leukemia lacking a human leukocyte antigen-matched donor. We analyzed 173 adults with acute myeloid leukemia (AML) and 93 with acute lymphoblastic leukemia (ALL) who received a haplo-HSCT in Europe. All grafts were T cell–depleted peripheral blood progenitor cells from a direct family or other related donor. At transplantation, there were 25 patients with AML in CR1 (complete remission 1), 61 in more than or equal to CR2, and 87 in nonremission, and 24 with ALL in CR1, 37 in more than or equal to CR2, and 32 in nonremission. Median follow-up was 47 months in AML and 29 months in the ALL groups. Engraftment was observed in 91% of the patients. Leukemia-free survival at 2 years was 48% plus or minus 10%, 21% plus or minus 5%, and 1% for patients with AML undergoing transplantation in CR1, more than or equal to CR2, and nonremission, and 13% plus or minus 7%, 30% plus or minus 8%, and 7% plus or minus 5% in ALL patients, respectively. In conclusion, haplo-HSCT can be an alternative option for the treatment of high-risk acute leukemia patients in remission, lacking a human leukocyte antigen-matched donor. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020